A clinically significant bronchodilator response in children: how should it be measured?
Eur Respir J
.
2020 May 7;55(5):2000636.
doi: 10.1183/13993003.00636-2020.
Print 2020 May.
Authors
Carmen C M de Jong
1
,
Eva S L Pedersen
1
,
R Mozun
1
,
Myrofora Goutaki
1
2
,
Daniel Trachsel
3
,
Juerg Barben
4
,
Claudia E Kuehni
5
2
Affiliations
1
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
2
Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Bern, Switzerland.
3
Paediatric Respiratory Medicine, Children's University Hospital of Basel, Basel, Switzerland.
4
Paediatric Respiratory Medicine, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.
5
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland claudia.kuehni@ispm.unibe.ch.
PMID:
32381634
DOI:
10.1183/13993003.00636-2020
No abstract available
Publication types
Letter
Comment
MeSH terms
Asthma* / drug therapy
Bronchodilator Agents* / therapeutic use
Child
Humans
Spirometry
Substances
Bronchodilator Agents